Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
339.04
-0.62 (-0.18%)
At close: Nov 12, 2024, 4:00 PM
340.00
+0.96 (0.28%)
After-hours: Nov 12, 2024, 5:32 PM EST
Madrigal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for MDGL stock have an average target of 347.33, with a low estimate of 150 and a high estimate of 441. The average target predicts an increase of 2.45% from the current stock price of 339.04.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for MDGL stock from 14 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Hold Maintains $194 → $236 | Hold | Maintains | $194 → $236 | -30.39% | Nov 5, 2024 |
| UBS | UBS | Strong Buy Maintains $411 → $441 | Strong Buy | Maintains | $411 → $441 | +30.07% | Nov 1, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $375 → $350 | Buy | Maintains | $375 → $350 | +3.23% | Oct 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $390 | Strong Buy | Reiterates | $390 | +15.03% | Oct 22, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Oct 11, 2024 |
Financial Forecast
Revenue This Year
172.73M
Revenue Next Year
506.90M
from 172.73M
Increased by 193.46%
EPS This Year
-24.11
from -19.99
EPS Next Year
-14.24
from -24.11
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 200.0M | 676.8M | 1.4B | ||
| Avg | 172.7M | 506.9M | 994.6M | ||
| Low | 154.6M | 289.2M | 508.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 291.8% | 175.8% | ||
| Avg | - | 193.5% | 96.2% | ||
| Low | - | 67.4% | 0.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -24.09 | -8.70 | 18.78 | ||
| Avg | -24.11 | -14.24 | 2.14 | ||
| Low | -24.02 | -25.82 | -21.46 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.